Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
66.19
0.06 (0.09%)
Market Cap: 12.61 Bil
Enterprise Value: 12.26 Bil
PE Ratio: 39.63
PB Ratio: 2.33
GF Score: 67/100 Biomarin Pharmaceutical Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 04, 2023 / 03:20PM GMT
Release Date Price:
$95.43
(-1.21%)
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Good morning, and thank you for joining us on day 2 of Guggenheim genomic medicines at our Disease Conference. I am Debjit the therapeutic analyst at Guggenheim. My privilege to host Brian Mueller, BioMarin's Executive VP and Chief Financial Officer. Thank you for your time today, Brian.
Brian R. Mueller
BioMarin Pharmaceutical Inc. - CFO & Executive VP
Thanks, Debjit. Appreciate you having us.
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Awesome. So before we get started with the Q&A, do you want to spend a minute just walking people through BioMarin now that the company needs any introduction.
Brian R. Mueller
BioMarin Pharmaceutical Inc. - CFO & Executive VP
Yes, absolutely. Thanks for the opportunity. I've got some opening remarks. I'd love to share, really appreciate the opportunity to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot